» Authors » Laurent Detalle

Laurent Detalle

Explore the profile of Laurent Detalle including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 17
Citations 427
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Smit J, Basile P, Prato M, Detalle L, Mathy F, Schmidt A, et al.
Mov Disord . 2022 Aug; 37(10):2045-2056. PMID: 35959805
Background: Parkinson's disease (PD) and its progression are thought to be caused and driven by misfolding of α-synuclein (ASYN). UCB0599 is an oral, small-molecule inhibitor of ASYN misfolding, aimed at...
2.
De Leeuw E, Van Damme K, Declercq J, Bosteels C, Maes B, Tavernier S, et al.
Respir Res . 2022 Aug; 23(1):202. PMID: 35945604
Background: The efficacy and safety of complement inhibition in COVID-19 patients is unclear. Methods: A multicenter randomized controlled, open-label trial. Hospitalized COVID-19 patients with signs of systemic inflammation and hypoxemia...
3.
Declercq J, Bosteels C, Van Damme K, De Leeuw E, Maes B, Vandecauter A, et al.
Trials . 2020 Nov; 21(1):934. PMID: 33213529
Objectives: Zilucoplan (complement C5 inhibitor) has profound effects on inhibiting acute lung injury post COVID-19, and can promote lung repair mechanisms that lead to improvement in lung oxygenation parameters. The...
4.
Cunningham S, Piedra P, Martinon-Torres F, Szymanski H, Brackeva B, Dombrecht E, et al.
Lancet Respir Med . 2020 Oct; 9(1):21-32. PMID: 33002427
Background: Respiratory syncytial virus (RSV) is the most common cause of severe lower respiratory tract infection, with a high global health burden. There are no effective treatments available. ALX-0171 is...
5.
Broadbent L, Guo Parke H, Ferguson L, Millar A, Shields M, Detalle L, et al.
Antimicrob Agents Chemother . 2019 Nov; 64(2). PMID: 31767728
Respiratory syncytial virus (RSV) causes severe lower respiratory tract infections in young infants. There are no RSV-specific treatments available. Ablynx has been developing an anti-RSV F-specific nanobody, ALX-0171. To characterize...
6.
Larios Mora A, Detalle L, Gallup J, Van Geelen A, Stohr T, Duprez L, et al.
MAbs . 2018 May; 10(5):778-795. PMID: 29733750
Respiratory syncytial virus (RSV) is a common cause of acute lower respiratory disease in infants and young children worldwide. Currently, treatment is supportive and no vaccines are available. The use...
7.
Palomo C, Mas V, Detalle L, Depla E, Cano O, Vazquez M, et al.
Antimicrob Agents Chemother . 2016 Aug; 60(11):6498-6509. PMID: 27550346
ALX-0171 is a trivalent Nanobody derived from monovalent Nb017 that binds to antigenic site II of the human respiratory syncytial virus (hRSV) fusion (F) glycoprotein. ALX-0171 is about 6,000 to...
8.
van Heeke G, Allosery K, De Brabandere V, De Smedt T, Detalle L, De Fougerolles A
Pharmacol Ther . 2016 Jul; 169:47-56. PMID: 27373507
Local pulmonary delivery of biotherapeutics may offer advantages for the treatment of lung diseases. Delivery of the therapeutic entity directly to the lung has the potential for a rapid onset...
9.
De Tavernier E, Detalle L, Morizzo E, Roobrouck A, De Taeye S, Rieger M, et al.
J Biol Chem . 2016 May; 291(29):15243-55. PMID: 27226529
Improving potencies through concomitant blockage of multiple epitopes and avid binding by fusing multiple (different) monovalent Nanobody building blocks via linker sequences into one multivalent polypeptide chain is an elegant...
10.
Larios Mora A, Detalle L, Van Geelen A, Davis M, Stohr T, Gallup J, et al.
PLoS One . 2015 Dec; 10(12):e0143580. PMID: 26641081
Rationale: Respiratory syncytial virus (RSV) infection in preterm and newborn infants can result in severe bronchiolitis and hospitalization. The lamb lung has several key features conducive to modeling RSV infection...